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Monoclonal antibodies have been generated to a chi- 
meric peptide comprised of Escherichia coli @-galac- 
tosidase fused to the amino acid sequence 69-207 of 
human preproenkephalin A. Two monoclonal antibod- 
ies,  PE- 1  and PE-2, were identified by their ability to 
recognize the same segment of proenkephalin A fused 
to the cII gene product of the E. coli bacteriophage X. 
The binding domains of PE-1 and PE-2 have been 
broadly located, with respect to the primary transla- 
tion product, within the amino acid sequences 152- 
207 and 84-131, respectively. Immunoblot analysis of 
total bovine adrenomedullary chromaffin granule ly- 
sate  reveals PE-1 and PE-2 immunoreactive forms of 
observed molecular mass 35,  33, 29, 24, 22, and 15 
kDA, and an 18-kDa  PE-1 immunoreactive form. Sep- 
aration of granule membranes from their contents re- 
veals differential membrane association of these high 
molecular weight polypeptides. There is preliminary 
evidence that PE-1 may  be detecting a subset of poly- 
peptides where shortening from the NH2 terminus has 
occurred. We postulate that the 35-kDa form repre- 
sents the intact bovine enkephalin precursor of pre- 
dicted molecular mass 27.3 kDa. This experimental 
approach should be generally applicable to the gener- 
ation of antibodies which will recognize intact peptide 
precursors together with their post-translational 
cleavage products. 
Proenkephalin A is one of the  three opioid precursor mol- 
ecules and gives rise to  the well  known  opioid pentapeptides 
Met-  and Leu-enkephalin. The primary  structure of preproen- 
kephalin A has been deduced in a number of mammalian 
species from the nucleotide sequence of its cloned cDNAs 
(Comb et al., 1982; Legon et al., 1982; Noda et al., 1982; 
Yoshikawa et al., 1984). The predicted molecular mass of 
proenkephalin A is approximately 27 kDa. There is an ex- 
tremely high  degree of sequence homology between the pro- 
enkephalin A molecules of different mammalian species, in- 
dicating that nonenkephalin as well as enkephalin regions 
have been conserved during evolution and so may have intrin- 
sic  biological importance. Within the precursor the enkepha- 
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lin sequences are flanked by pairs of basic residues which are 
potential  sites of proteolytic cleavage. Thus, complete proc- 
essing of the precursor molecule  will  yield four copies of Met- 
enkephalin and one copy each of Leu-enkephalin, Met-en- 
kephalin-Arg6-Gly7-Leu’ and Met-enkephalin-Arg6-Phe7. 
However, incomplete processing has the potential to yield 
many different extended enkephalin-containing peptides. In- 
deed a wide array of such peptides has been identified, many 
of which have been isolated and characterized, mainly from 
bovine adrenal medulla (for review see Udenfriend and Kil- 
patrick, 1983). There  is evidence that some of these  extended 
forms may be even more  biologically active than  the originally 
described pentapeptides. For example, peptide E, Bam-22P, 
and Bam-20P have been shown to be more potent in the 
guinea pig ileum bioassay than Met-  or Leu-enkephalin (Kil- 
patrick et al., 1981; Mizuno et al., 1980). More recently, even 
larger peptides have been detected; for example, synenke- 
phalin which does not  contain an enkephalin sequence (Liston 
et al., 1983), and peptides of predicted molecuIar mass 8.6 
kDa,’ 12.6 kDa (Jones et al., 1982), 18.2 kDa (Kilpatrick et 
al., 1982), and 23.3 kDa (Patey et al., 1984) (Fig. 1). The 
biological significance of these high molecular mass polypep- 
tides remains to be determined. 
Studies focusing on the high molecular weight forms of 
proenkephalin have often been limited because of the fact 
that  the majority of antibodies currently available has been 
raised to small synthetic  enkephalin  and nonenkephalin pep- 
tides. Such antibodies therefore exhibit limited immune rec- 
ognition of the  parent prohormone. Consequently, the detec- 
tion of larger forms usually requires proteolytic liberation of 
the smaller peptides from their larger precursors after chro- 
matographic separation. One possible solution would be to 
immunize with purified intact  enkephalin precursor, but  this 
is impractical as  the prohormone has  not been convincingly 
identified, possibly because of its  instability  and low abun- 
dance. In  this work, therefore, we chose to synthesize proen- 
kephalin A as a fusion protein with @-galactosidase in an 
Escherichia coli expression system. The method is particularly 
suitable in this context as it could be anticipated that a 
prohormone would be afforded protection from degradation 
when expressed as  a fusion protein within a bacterial milieu. 
Furthermore, because of its conjugation to a highly immuno- 
genic bacterial protein, it is in the form of a ready-made 
“hapten-carrier” complex. In  this paper we demonstrate  our 
success in utilizing this approach to raise monoclonal anti- 
bodies  which  may  recognize the naturally occurring precursor 
proenkephalin A together with a wide range of intermediates. 
Peptides that have been named according to their predicted 
molecular mass (8.6, 12.6, 18.2, and 23.3 kDa)  are denoted in italics. 
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EXPERIMENTAL PROCEDURES~ 
RESULTS 
Production of @-Galactosidase-Preproenkephalin-A-(69- 
207) Fusion Protein for Immunization-A human preproen- 
kephalin A cDNA clone (Legon et al., 1982) was used to 
generate a 411-base pair restriction fragment encoding the 
amino acid sequence 69-207  of the primary gene product (Fig. 
1, PPE-(69-207)). This was cloned into the PUR series of 
expression vectors (Ruther and Muller-Hill, 1983) as de- 
scribed under “Experimental Procedures.” These vectors pos- 
sess a series of unique restriction enzyme sites at  the 3‘  end 
of the E. coli  lac Z gene, the expression of which is driven by 
its  natural  promoter  and  operator.  The cloning sites  are in 
different reading frames with respect to  the lac 2 gene in the 
three different vectors. The segment of preproenkephalin A 
cDNA was cloned in translational phase with the COOH 
terminus of @-galactosidase in  the vector PUR 291. Recom- 
binant plasmids were transformed  into  competent cells of the 
E. coli strain  BMH 71-18, which lacks the endogenous lac 2 
gene but  carries the lac iQ mutation which confers the phe- 
notype of overproduction of the lac repressor. Thus, despite 
the high  copy number of the plasmid, expression of the fusion 
* “Experimental Procedures” are presented in miniprint at the end 
of this paper. Miniprint is easily read with the aid of a standard 
magnifying glass. Full size photocopies are included in the microfilm 
edition of the Journal that is available from  Waverly Press. 
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protein should be suppressed until addition of the  synthetic 
inducer IPTG.3 
To identify which colonies contained the insert in the 
correct orientation  and  translational  phase,  a random selec- 
tion of transformants were cultured in L-broth in the presence 
of IPTG. Crude bacterial lysates were made by sonicating the 
cells in SDS sample buffer and electrophoresed on  7.5% 
denaturing polyacrylamide gels (see “Experimental Proce- 
dures” ). Production of @-galactosidase-proenkephalin A fu- 
sion protein was easily identified by Coomassie staining of 
the gels, the hybrid polypeptide being more abundant and 
migrating more slowly than unfused 0-galactosidase (Fig. 2, 
lane 2). Restriction endonuclease cleavage analysis of plasmid 
DNA from the positive colonies confirmed the presence of the 
enkephalin insert in the correct orientation. Bacterial lysates 
were then fractionated on preparative SDS-polyacrylamide 
gels in order to obtain sufficient fusion protein for immuni- 
zation. A 100-ml bacterial culture yielded approximately 10- 
15 mg  of fusion protein electrophoretically purified from the 
excised gel band (Fig. 2, lane 4 ) .  The lower band of the doublet 
represents proteolytically liberated 0-galactosidase. The hy- 
brid protein was used directly as  an immunogen in rabbits 
and BALB/c mice. 
Production of a Secondary cII-Preproenkephalin A-(69-207) 
Fusion Protein for Screening of Sera and Monoclonal Super- 
natants-In anticipation that  the P-galactosidase-preproen- 
The abbreviations used are: IPTG, isopropylthiogalactoside; SDS, 
sodium dodecyl sulfate; PAGE, polyacrylamide gel electrophoresis; 
IGSS, immunogold silver staining; PBS, phosphate-buffered saline; 
PMSF, phenylmethanesulfonyl fluoride; BSA, bovine serum albumin; 
FCS, fetal calf serum. 
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FIG. 1. Schematic representation of the binding domains of the monoclonal antibodies PE- 1 and PE- 
2 in relation to the primary structure of preproenkephalin A. The central boxed region illustrates the intact 
precursor. The lower portion of the diagram shows some of the high molecular weight proteolytic cleavage products 
of proenkephalin A.  The upper section illustrates the cDNA fragments used to generate fusion proteins for 
immunization or epitope mapping. 
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FIG. 2. Appearance of &galactosidase-preproenkephalin 
A-(69-207)  fusion  protein on a Coomassie-stained  denaturing 
polyacrylamide gel. Lanes 1 and 2 represent total lysates of  bacteria 
transformed  with the recombinant  plasmid pB-gal-(PPE-69-207), cul- 
tured in the absence (lane l )  or  presence  of  IPTG (lane 2). The fusion 
protein  can  be seen as the uppermost band in lane 2. The lower band 
of the doublet represents proteolytically liberated @-galactosidase. 
Lane 4 shows the appearance  of the fusion protein after  electropho- 
retic  purification. Lane 3 shows  unfused  &galactosidase  for  compar- 
ison. Positions of molecular mass markers  are  shown on the extreme 
right. 
kephalin A fusion protein would elicit a pronounced anti-b- 
galactosidase response another gene fusion was  made  which 
would direct the synthesis of an identical enkephalin sequence 
fused to a different prokaryotic gene product. This could 
therefore be used directly to test sera  and hybridoma culture 
medium  for anti-proenkephalin activity without the need for 
a double screening procedure. The proenkephalin sequence 
was subcloned  from pUR291 into plcII (Nagai and Thbgersen, 
1984) to position it  at the 3’ end of a sequence encoding the 
NHz-terminal31 amino acids of the phage X cl l  gene product, 
under control of the X PL promoter (see “Experimental Pro- 
cedures” ). The recombinant plasmid was transformed into 
the lysogenic E. coli strain QY-13, in which the prophage 
carries the mutation cIa7 which  encodes a temperature-sen- 
sitive repressor. Thus, when the bacteria are grown at  30 “C, 
the repressor is  fully active and  transcription is prevented. 
However,  when the temperature is raised to 42 “C, the repres- 
sor becomes unstable and expression of the fusion protein is 
allowed. When lysates of these cells are subjected to SDS- 
PAGE, the cII-preproenkephalin A-(69-207) fusion protein 
can be seen on a Coomassie-stained gel as a plasmid-specified 
23-kDa protein present in cultures grown at  42 “C  but  not in 
cultures grown at 30 “C (see Fig.  3, panel  a). The identity of 
this fusion protein was confirmed by Western blotting of 
these bacterial lysates. The blots were incubated with a rabbit 
polyclonal antiserum (R139) which had been raised to  the B- 
galactosidase-preproenkephalin A-(69-207) fusion protein. 
Prior to immunostaining, the rabbit antiserum was preab- 
sorbed using a crude E. coli lysate coupled to a cyanogen 
bromide-activated Sepharose column to remove antibodies to 
endogenous E. coli antigens as far as possible. This antiserum 
identifies the cII-preproenkephalin A-(69-207) fusion protein 
whereas the preimmune serum does not (Fig. 3, panel b) .  The 
remaining strips in this blot demonstrate the results of im- 
munostaining identical material using antisera raised against 
the pentapeptide Met-enkephalin and  the octapeptide Met- 
enkephalin-Arg6-Gly7-hu8. These sequences are present in 
the cDNA segment in three  and one copies,  respectively. Both 
antisera recognize the 23-kDa peptide confirming its identity 
as  the cII-preproenkephalin A fusion protein. 
Generation of Monoclonal  Antibodies, PE-1 and  PE-2”Sera 
from BALB/c  mice immunized with the B-galactosidase-pre- 
proenkephalin A-(69-207) hybrid polypeptide were tested for 
antiproenkephalin activity by immunoblotting against bacte- 
rial lysate expressing the cII-preproenkephalin A-(69-207) 
fusion peptide. The sera were again preabsorbed using E. coli 
lysate immobilized on a Sepharose column. A clear anti- 
proenkephalin response was observed after a total of six 
injections of immunogen. 
The spleens of the two  mice with the strongest peripheral 
response were  used to generate hybridoma clones. Clones were 
screened by testing  supernatants from the microtiter wells 
against nitrocellulose strips of immunoblotted cII-preproen- 
kephalin A-(69-207) prepared from Western blots of total 
bacterial lysate as described under “Experimental Proce- 
dures.’’ Out of nine original positive clones, two  were charac- 
terized and designated PE-1  and PE-2. 
Characterization and Preliminary Epitope Mapping of PE- 
1 and  PE-2”In order to map the binding regions of PE-1 
and  PE-2 on the primary structure of the precursor, a series 
of B-galactosidase-preproenkephalin A fusion peptides incor- 
porating overlapping regions of sequence was constructed. For 
this  part of the study a cDNA clone extending over the  entire 
protein coding  region, amino acids 1-267, was used (Comb et 
al.,  1982). The cDNA  was  cleaved at  a variety of restriction 
endonuclease sites to generate a series of cDNA fragments 
which  were cloned into the PUR vectors (see “Experimental 
Procedures” ). The products of ligation were transformed into 
E. coli strain  TG2 which  is lac 2-, lac iQ. Recombinants were 
identified by  colony hybridization using a radiolabeled pre- 
proenkephalin cDNA probe, and  the orientation of the insert 
was confirmed by restriction endonuclease digests of purified 
plasmids. The ability of the constructs to direct the synthesis 
of fusion proteins was confirmed by analyzing total bacterial 
lysates by SDS-PAGE as described under “Experimental Pro- 
cedures.,’ The following hybrid polypeptides were generated 
in  this way: 8-galactosidase-preproenkephalin A-( 1-267), -( 1- 
131), -(130-267),  -(1-84),  -(84-154),  -(152-267)  (Fig. 1). 
Fig. 4 illustrates the results of immunoblot analysis of these 
fusion peptides. It can be seen that  PE-1 recognizes 8-galac- 
tosidase-preproenkephalin A-( 1-267) and -( 130-267), to- 
gether with the original immunogen, -(69-207). PE-1 also 
binds &galactosidase-preproenkephalin A-( 152-267) (not 
shown). PE-2 recognizes j3-galactosidase-preproenkephalin A- 
(1-267), -(l-131), -(84-154), and the original immunogen 
-(69-207). 8-Galactosidase-preproenkephalin A-(1-84) is rec- 
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FIG. 3. Appearance of cII-preproenkephalin A-(69-207) fusion protein. Panel a, appearance on  a 10% 
Coomassie-stained SDS-polyacrylamide gel. Lune M ,  molecular mass standards. Lune 1, total lysate of host bacteria 
transformed with the parent vector pLcII, cultured at  42 "C. Lunes 2 and 3, total lysates of bacteria transformed 
with the recombinant plasmid pcII-PPE-(69-207), cultured at  30 "C (lane 2 )  or 42 "C (lane 3, fusion protein visible 
a t  -23 kDa). Panel b, immunoblot analysis of identical material (lanes 1, 2, and 3 as for p a n e l  a).  Nitrocellulose 
strips were immunostained with different polyclonal antisera using a peroxidase detection method. Antisera were 
as follows: P.Z., a  rabbit preimmune serum as a negative control; R139, a  rabbit polyclonal antiserum obtained 
after immunization with the 0-galactosidase-preproenkephalin A-(69-207) fusion protein; MET-8, a polyclonal 
antiserum to  the octapeptide Met-enkephalin-Arg6-Gly7-Leu8; M E T 4  a polyclonal antiserum to  the pentapeptide 
Met-enkephalin. All polyclonal antisera  had been preabsorbed using a crude E. coli lysate coupled to a CNBr- 
activated Sepharose column. 
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FIG. 4. Preliminary epitope mapping of PE-1 and PE-2 by 
immunoblot analysis  of a series of 8-galactosidase-preproen- 
kephalin A fusion proteins (see also Fig. 1). Total bacterial 
lysates were subjected to Western blotting followed  by immunostain- 
ing with either PE-1 (left-hand strip) or PE-2 (right-hand strip). In 
each case, lanes 1-6 represent &galactosidase fusion proteins  in the 
following order: j3-gal-PPE-(1-267), -(69-207), -(1-131), -(130-267), 
-(1-84), and -(84-154). 
ognized by neither antibody. Thus  the binding domains of 
PE-1  and  PE-2 can be broadly  located, with respect to  the 
primary translation product, within the amino acid  sequences 
152-207 and 84-131, respectively  (Fig. 1). 
Subclass determination of the hybridoma  clones  was carried 
out by incubation of monoclonal supernatants with purified 
fusion protein spotted onto nitrocellulose followed  by immu- 
noperoxidase detection using subclass-specific second anti- 
bodies. PE-1  and  PE-2 were both found to be of subclass IgGI. 
Demonstration That  PE-1 and PE-2 Recognize Naturally 
Occurring High Molecular Weight Proenkephalin A-derived 
Peptides-In order to determine whether the monoclonal 
antibodies would  recognize naturally occurring proenkephalin 
A-derived  peptides, we prepared bovine adrenomedullary 
chromaffin granule lysates as described under "Experimental 
Proce9ures." In  the  first instance, acidic lysates were made 
by sonication of isolated granules in 0.1 M HCI plus protease 
inhibitors in order to limit proteolytic  processing. The sam- 
ples were then subjected to SDS-PAGE using a 12% separat- 
ing gel  followed  by immunoblot  using a peroxidase detection 
method. This revealed that  PE-1  and PE-2 recognize  forms 
of observed  molecular  mass 35,33,29,24,22,  and 15  kDa.  An 
18-kDh  form is recognized by PE-1 alone, which  may therefore 
represent an NHz-terminally shortened form (Fig. 5). The 
24-,  22-, and 15-kDa forms also  recognized  by PE-1, which 
apparently comigrate  with PE-2 immunoreactive  forms, may 
represent other NHz-terminally shortened forms (see "Dis- 
cussion" ). To our knowledge these PE-1 immunoreactive 
forms  have not been  described  previously nor have the 35- 
and 33-kDa forms. Both antibodies also recognize bovine 
proenkephalin A-derived peptides in chromaffin granule  ly- 
sates after chromatographic separation and assay of fractions 
in an enzyme-linked immunosorbent assay system. These 
data are described  in detail elsewhere.' 
The Distribution of PE-1 and PE-2 Immunoreactive Pep- 
tides withzn Chromaffin Granules-Studies by others have 
suggested that high molecular weight proenkephalin A-de- 
'Jackson, S., Spruce, B. A., Glynn, B., Glover, D. M., and Low, 
P. J., J. Mol. Endocrinol., in press. 
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FIG. 5. Immunoblot analysis of bovine adrenomedullary chromaffin granule lysates. Panel a, peroxi- 
dase detection method used (diaminobenzidine stain). In all cases, lane 1 represents total granule lysate, lane 2, 
the granule contents, and lane 3, the membrane fraction. Nitrocellulose strips were immunostained with PE-1 or 
PE-2 supernatants, or a polyclonal antiserum to  the membrane protein p38. Panel b, IGSS detection method used. 
Lanes 1,2,  and 3 as for panel a. 
rived peptides are associated with the granule membrane 
(Hook and Liston, 1987; Birch et al., 1986).  We  were therefore 
interested to find which of the  PE-1 and PE-2 immunoreac- 
tive peptides were membrane-bound. In order to separate 
granule contents from membranes, total granule lysates were 
subjected to high speed centrifugation in an air-driven ultra- 
centrifuge. Supernatant  and pellet were carefully separated, 
the former representing the contents  and the latter the mem- 
brane fraction. Equivalent amounts of each fraction were 
subjected to SDS-PAGE followed by immunoblotting using a 
peroxidase detection method with diaminobenzidine as sub- 
strate. All  of the forms present  in  total lysate can be detected 
in the soluble fraction. In addition, the 29-,  22-, and 15-kDa 
PE-2 immunoreactive forms are all associated with the gran- 
ule membrane, the proportion bound decreasing with dimin- 
ishing molecular  size. Using the same detection method, the 
PE-1 immunoreactive forms migrating at  29 and 24 kDa 
appeared to be membrane-bound (Fig. 5, panel a). 
It was felt that  the failure to detect membrane binding of 
the highest molecular weight forms could be a problem of 
detection, since they were less abundant in total lysates. We 
therefore employed an immunochemical detection method 
utilizing a gold-coupled second antibody followed by silver 
enhancement in order to increase sensitivity (IGSS). This 
revealed that  the 35-kDa form recognized  by PE-1 and  PE-2 
is indeed membrane-bound, although the 33-kDa form is 
not (Fig. 5, panel b). Furthermore, the increased sensitivity 
of the IGSS system revealed that  the  PE-1 immunoreactive 
22-, 18-, and 15-kDa forms are membrane-bound and con- 
firmed membrane association of the 29- and 24-kDa forms 
(see Fig.  5, p a n e l  b). IGSS confirmed membrane binding of 
the 29-,  22-, and 15-kDa forms recognized by PE-2  and the 
absence of membrane association of the 24-kDa PE-2 immu- 
noreactive form (data  not shown). 
Using IGSS, we observed that only a minor proportion of 
the 35-kDa  form  was membrane-bound. However, immuno- 
staining of the fractions with a polyclonal antiserum to p38, 
an intrinsic membrane protein, showed that p38 was clearly 
present in the soluble fraction, suggesting there had been 
incomplete separation of membrane from contents. Moreover, 
we were concerned that lysis of the granules under acidic 
conditions could  have  dislodged the precursor from the mem- 
brane. We therefore repeated the experiment using hypotonic 
lysis in 5 mM Tris succinate at pH 5.9 accompanied by freeze- 
thawing. Under these circumstances, however, the overall 
amounts of enkephalin peptides were substantially reduced 
and the highest molecular  weight form visible in any of the 
fractions was the 29-kDa form, suggesting that significant 
proteolysis had occurred despite the presence of protease 
inhibitors (data  not shown). 
DISCUSSION 
We have used a @-galactosidase-preproenkephalin A chi- 
meric protein, synthesized in E. coli, to generate monoclonal 
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antibodies which are likely to have the capacity to recognize 
the naturally occurring enkephalin precursor proenkephalin 
A together with a range of processed products. 
A number of antibodies to proenkephalin A-derived pep- 
tides  are available, but  these have usually been generated to 
small synthetic enkephalin- and nonenkephalin-containing 
peptides. Many of these antibodies cannot be used in direct 
assays for naturally occurring high molecular weight peptides, 
suggesting significant tertiary conformation of these precur- 
sor forms. An exception to  this is an antiserum raised to a 
synthetic peptide corresponding to residues 95-117  of bovine 
proenkephalin A (Christie et al., 1984; Birch and Christie, 
1986). This antibody recognizes a wide range of high molec- 
ular weight intermediates  and may also have the capacity to 
recognize the  intact precursor. Another group has raised an 
antiserum to purified bovine adrenal medullary proenkephalin 
A (1-77)  which has been used successfully to purify the 8 6 ,  
1 2 6 ,  18.2-, and 23.3-kDa peptides (Metters and Rossier, 
1987). However, the usefulness of such antibodies when em- 
ployed in isolation is bound to be limited as  it  has become 
apparent that there may not be a fixed site for the first 
cleavage event of the  intact precursor. Thus  an even greater 
number of high molecular weight intermediates could exist 
than was originally envisaged. This is supported by the finding 
of NHz-terminally shortened forms in which the extreme 
COOH terminus of proenkephalin (Met-enkephalin-Arg6- 
Phe7) is still present (Baird et al., 1984). Thus, in order to 
gain a fully comprehensive picture of the biosynthetic path- 
ways, there is a requirement for a comprehensive range of 
antibodies directed to different regions of the precursor which 
will  recognize the uncleaved prohormone, together with proc- 
essed products. This facility would  be particularly important 
where rapid marked changes in enkephalin gene transcription 
are occurring, for example in the hypothalamus in response 
to stress (Lightman and Young, 1987). Here, accurate esti- 
mation of the primary translation product, together with 
processed peptides, would  be crucial. 
The major proenkephalin A-derived peptides detected by 
us in bovine chromaffin granule isolates migrated on  SDS- 
PAGE with apparent masses of 35,  33,  29,  29, 22, 18, and  15 
kDa. In 1982 Dandekar  and Sabol detected an enkephalin- 
containing precursor in  the cell-free translation products of 
bovine adrenal medullary mRNA which migrated at 31 kDa 
on SDS-PAGE. Since the experiment was carried out  in the 
absence of pancreatic microsomes the 24-residue signal se- 
quence would  be expected to contribute 2-3 kDa; therefore, 
bovine proenkephalin should migrate at approximately 28-29 
kDa on SDS-PAGE in the absence of post-translational mod- 
ifications. Beaumont et al. (1985) identified a proenkephalin 
peptide in guinea pig striatum which migrated at 31 kDa on 
SDS-PAGE. The presence of Met-enkephalin-Arg6-Phe7 im- 
munoreactivity in  the corresponding chromatographic frac- 
tion led them to postulate that  this represented the  intact 
enkephalin precursor. To date, the highest molecular weight 
forms reported to exist in bovine adrenal medulla are 27 kDa 
(Birch  and Christie, 1986) and 28 kDa (Metters  and Rossier, 
1987), as determined by SDS-PAGE. However, cross-immu- 
noreactivity studies indicate that these forms are likely to 
correspond to the 23.3-kDa peptide rather than the intact 
enkephalin precursor. It seems highly likely that  the 29-kDa 
form observed by us is in fact also this 23.3-kDa peptide, 
raising the possibility that  the 35/33-kDa doublet represents 
the  intact enkephalin precursor. 
The 18.2- and 12.6-kDa peptides have also been shown to 
migrate anomalously slowly on SDS-PAGE (Kilpatrick et  al., 
1982). Comparison of our immunoblot data with those of 
others  (Patey et al., 1984; Birch et  al., 1986;  Hook and Liston, 
1987) suggests that  the 22- and 15-kDa forms recognized by 
PE-2 correspond, respectively, to the 18.2- and 12.6-kDa 
peptides. Further  studies by us suggest that  this is indeed the 
The 24-kDa form may represent  a  post-translationally 
modified form of the 18.2-kDa peptide which has been ob- 
served by others to migrate as two species. We initially 
assumed that  the 24- and 22-kDa forms recognized  by PE-1 
were also likely to correspond to the 18.2-kDa peptide in 
modified and unmodified form. However, further  studies by 
us indicate that  the  PE-1 epitope may lie outside the sequence 
which gives rise to  the 18.2-kDa peptide. For example, PE-1 
fails to bind the purified bovine 5.3-kDa peptide in  an enzyme- 
linked immunosorbent assay system5 (Fig. 1). Given their 
apparent molecular weights, it is therefore possible that  the 
24- and 22-kDa PE-1 immunoreactive forms represent high 
molecular weight polypeptides where shortening from the 
NH2  terminus of the precursor has occurred. Additionally, the 
PE-1 immunoreactive 15-kDa form cannot correspond to  the 
predicted molecular mass 12.6-kDa peptide which does not 
contain the PE-1 epitope (see Fig. 1) and must therefore 
represent a polypeptide which extends further toward the 
COOH terminus of the precursor. The 18-kDa form specific 
to PE-1  is also likely to represent  another novel NHz-termi- 
nally shortened peptide since it apparently does not  contain 
the PE-2 epitope. However, post-translational modification 
within the region of the  PE-2 epitope, preventing binding of 
PE-2, cannot at this stage be ruled out. We are currently 
purifying these peptides in order to define their  structure. 
To investigate the possibility that  the 33/35-kDa doublet 
may indeed represent the intact enkephalin precursor, we 
decided to look at  the association of these peptides with the 
granule membrane. It is known that hormone precursors are 
membrane-bound, which  may provide a mechanism for cor- 
rect sorting  and  orientation for proteolytic processing. Several 
prohormones, for example proinsulin, proglucagon, prosoma- 
tostatin, and proopiomelanocortin, have been shown to be 
associated with secretory granule membranes (Noe  and 
Moran, 1984; Loh and Tam, 1985). In this study we have 
shown that  the  PE-2 immunoreactive 29-, 22-, and 15-kDa 
forms are all membrane-bound, the proportion bound decreas- 
ing with diminishing molecular size (Fig. 5, panel a ) .  This is 
in keeping with the findings of others (Birch et al., 1986; 
Hook and  Liston, 1987). When the sensitivity of the immu- 
noblot system was increased by the use of immunogold silver 
staining we found that  the 35-kDa form was associated with 
the membrane, although the 33-kDa form was not. This would 
indicate that  the 35-kDa form may represent the  intact  en- 
kephalin precursor. If the 24-kDa PE-2 immunoreactive form 
is a modified form of the predicted molecular mass 18.2-kDa 
peptide, as  has been suggested by others,  then its  apparent 
failure to associate with the membrane could be related to 
post-translational modification. By the same argument, the 
33-kDa peptide could therefore be a modified processed form, 
for example a modified form of the 23.3-kDa peptide, the 
modification possibly preventing membrane association. As 
already stated, we are  postulating that  the 24-,  22-, 18-,  and 
15-kDa PE-1 immunoreactive peptides may represent  a subset 
of high molecular weight NHz-terminally  shortened polypep- 
tides, and it was therefore of interest to us to note that all 
these  forms appeared membrane-associated (see Fig.  5, panel 
b). This could indicate that proteolytic shortening of the 
membrane-bound forms is occurring from both ends of the 
molecule, suggesting the possibility that the region of the 
S. Jackson, unpublished data. 
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precursor which is attached to the membrane is centrally 
located. 
It was of some concern to us to note that only a minor 
proportion of the 35-kDa form was membrane-bound, the 
majority apparently remaining in  the soluble fraction. This 
fact may indicate that the 35-kDa form is not the intact 
enkephalin precursor, as the studies looking at membrane 
association of other prohormones found that they were ap- 
proximately 80% membrane-bound (Noe and Moran, 1984; 
Loh and  Tam, 1985).  However, these  studies looked at newly 
synthesized prohormone only and did not examine steady 
state levels. Another possible reason for the discrepancy is 
that we failed to achieve complete separation of membrane 
from contents.  This was indicated when an antiserum to  the 
intrinsic membrane protein p38, which has been recently 
demonstrated to be present in dense core granule membranes 
(Lowe et al., 1988), revealed significant amounts of p38 in the 
soluble fraction. A further experimental artifact could  have 
been introduced by our acidic lysis of the granules which  may 
have dislodged some of the precursor forms from the granule 
membrane. Studies by others suggest this is a possibility 
(Birch et al., 1986). We therefore repeated the experiment 
using hypotonic lysis at pH 5.9 accompanied by freeze-thaw- 
ing.  However, under these conditions the overall amounts of 
enkephalin peptides were substantially reduced and  the high- 
est molecular weight  form observed was the 29-kDa peptide. 
This indicates that significant artifactual proteolytic process- 
ing had occurred, despite the presence of protease inhibitors 
and  the fact that  in  the granule preparation we employed a 
final centrifugation step through 1.8 M sucrose in order to 
minimize  lysosomal contamination (Evangelista et al., 1982). 
In conclusion, we have used a novel approach in generating 
monoclonal antibodies to a complex neuropeptide precursor, 
preproenkephalin A. Despite the expression of the proen- 
kephalin sequence as  a fusion protein in an alien environment, 
the antibodies resulting from its use as  an immunogen are 
clearly able to recognize naturally occurring proenkephalin 
A-derived peptides. The antibodies PE-1  and  PE-2 may be 
recognizing the  intact bovine enkephalin precursor, although 
further evidence for this is required. They appear also to 
recognize a wide range of high molecular weight intermediates, 
and  there is preliminary evidence that a previously unidenti- 
fied subset of high molecular weight NH2-terminally short- 
ened forms may exist. Having successfully applied this  ap- 
proach to one of the most complex and unstable of the 
neuropeptide precursors, we are confident in predicting that 
the method will be widely applicable to other propeptide 
molecules. 
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